Overview

GP Extended Action Triptorelin

Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate that treatment with a 6-monthly injection of hormone therapy is as good and as well tolerated as the standard 3-monthly hormone therapy injections available for treating prostate cancer. The study will also aim to answer whether both doctors and patients would prefer treatment with a 6-monthly injection rather than injections every 3 months.
Phase:
Phase 4
Details
Lead Sponsor:
Ipsen
Treatments:
Goserelin
Leuprolide
Triptorelin Pamoate